Get us live on http://www.ripplesadvisory.com/free-trial.php
Share price of Ajanta Pharma gained 2.5 percent intraday on USFDA approval for Duloxetine hydrochloride delayed release capsules. Duloxetine is a bioequivalent generic version of Cymbalta delayed release capsules and part of an ever growing portfolio of products that the company has developed for the US market.
The company will launch the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules. The company has 32 abbreviated new drug application (ANDA) of which it has 17 final ANDA approvals, 2 tentative approvals and 13 ANDAs under review with USFDA.
Share price of Ajanta Pharma gained 2.5 percent intraday on USFDA approval for Duloxetine hydrochloride delayed release capsules. Duloxetine is a bioequivalent generic version of Cymbalta delayed release capsules and part of an ever growing portfolio of products that the company has developed for the US market. 
No comments:
Post a Comment